Oral presentation highlights remedy with TNX-102 SL (sublingual cyclobenzaprine HCl) within the Section 3 RESILIENT research exhibiting improved fibromyalgia damage ache and all six key secondary endpoints together with sleep high quality Statistically vital enchancment
Poster highlights different TNX-102 SL applications in medical improvement, together with acute stress issues
Poster demonstrates automated high-throughput assay enabling screening of therapeutics to speed up wound therapeutic
Chatham, N.J., Aug. 21, 2024 (GLOBE NEWSWIRE) — Tonix Prescribed drugs Holding Corp. (Nasdaq: TNXP) (Tonix or the Firm), an organization with marketed merchandise and a pipeline of improvement product candidates , a completely built-in biopharmaceutical firm, at present introduced that representatives from the corporate will ship oral displays and current on the 2024 Navy Well being Techniques Analysis Symposium (MHSRS) in Kissimmee, Florida, August 26-29, 2024 Three posters.
Copies of the corporate’s oral displays and posters can be out there on the Tonix web site at www.tonixpharma.com underneath the Scientific Stories tab following the convention. Further convention data may be discovered on the MHSRS web site.
Oral report
| host: | Seth Lederman, MD, CEO, Tonix Prescribed drugs |
| Assembly: | Lowering ache: new ache remedies |
| Efficacy and security of bedtime TNX-102 SL (sublingual cyclobenzaprine hydrochloride) within the remedy of fibromyalgia: outcomes from the confirmatory section 3 randomized, double-blind, placebo-controlled RESILIENT trial | |
| Date/Time: | Tuesday, August 27, 2024 1:00 pm ” 3:00 pm Japanese Time |
poster show
| host: | Megan Parmenter, Ph.D., Massachusetts Basic Hospital |
| Two medical trials of sublingual cyclobenzaprine (TNX-102 SL) at bedtime for the remedy of military-related post-traumatic stress dysfunction (PTSD) are investigating TNX-102 SL in decreasing acute stress dysfunction (ASD) and stopping PTSD after trauma. offered a foundation | |
| Date/Time: | Tuesday, August 27, 2024 3:00 pm ” 5:00 pm Japanese Time |
| host: | Sina (BitStamp:) Bavari, Ph.D., Government Vice President, Infectious Illness R&D, Tonix Prescribed drugs |
| Integrating automated high-throughput scratch assays and cell staining for complete evaluation of cell migration and wound therapeutic | |
| Date/Time: | Wednesday, August 28, 2024, 1:00 – 3:00 pm ET |
| host: | Samuel McLean, MD, Professor of Psychiatry and Emergency Medication, College of North Carolina College of Medication |
| Improvement of the AURORA Platform Trial Community to Check Interventions to Scale back Acute Stress Response Signs and Directions for Use of Testing Sublingual Cyclobenzaprine TNX-102 SL | |
| Date/Time: | Tuesday, August 27, 2024 3:30 PM “5:30 PM ET. |
Tonix Pharmaceutical Holdings Inc.
Tonix is an built-in biopharmaceutical firm centered on the event, licensing and commercialization of therapies to deal with and stop human illness and relieve struggling. Tonix not too long ago introduced that the U.S. Division of Protection (DoD) Protection Menace Discount Company (DTRA) has awarded it a five-year, $34 million contract in an Different Transaction Settlement (OTA) to develop the TNX-4200 small Molecular Broad-Spectrum Antivirals Medication that concentrate on CD45 are used to stop or deal with infections to enhance the medical preparedness of navy personnel in biothreat environments. Tonix owns and operates a state-of-the-art infectious illness analysis facility in Frederick, Maryland. The corporate’s state-of-the-art Good Manufacturing Follow (GMP) manufacturing facility in Dartmouth, Massachusetts, is devoted to the manufacturing of TNX-801, and the GMP suite is able to restart within the occasion of a nationwide or worldwide emergency. Tonix’s improvement portfolio focuses on central nervous system (CNS) illnesses. Tonix’s first precedence is to submit a New Drug Utility (NDA) to the FDA within the second half of 2024 for TNX-102 SL, a product candidate that has accomplished two statistically vital Section 3 research for the remedy of fibromyalgia. The FDA has granted Quick Observe designation to TNX-102 SL for the remedy of fibromyalgia. TNX-102 SL can be being developed to deal with acute stress reactions. Tonix’s CNS portfolio consists of TNX-1300 (cocaine esterase), a biologic designed to deal with cocaine intoxication with Breakthrough Remedy designation. Tonix’s immunology improvement portfolio consists of biologics that handle organ transplant rejection, autoimmunity and most cancers, together with TNX-1500, a humanized monoclonal antibody directed towards the CD40 ligand (CD40L or CD154), which is being developed Developed to stop allograft rejection and deal with autoimmune illnesses. Tonix additionally develops product candidates within the areas of uncommon illnesses and infectious illnesses. Our business subsidiary Tonix Medicines markets Zembrace ® SymTouch ® (sumatriptan injection) 3 mg and Tosymra ® (sumatriptan nasal spray) 10 mg for the remedy of acute migraine with or with out aura in adults.
Tonix’s product improvement candidates are investigational new medicine or biologics that haven’t but been authorized for any indication.
Zembrace SymTouch and Tosymra are registered emblems of Tonix Medicines. All different emblems are the property of their respective house owners.
This press launch and extra details about Tonix may be discovered at www.tonixpharma.com.
forward-looking statements
Sure statements on this press launch are forward-looking statements inside the which means of the Personal Securities Litigation Reform Act of 1995. These forward-looking statements are based mostly on Tonix’s present expectations and precise outcomes could differ materially. There are a lot of components that would trigger precise occasions to vary materially from these indicated by such forward-looking statements. These components embrace, however will not be restricted to, dangers associated to failure to acquire FDA clearance or approval and non-compliance with FDA laws; dangers associated to failure to efficiently market any of our merchandise; dangers associated to the timing and progress of medical improvement of our product candidates ; our want for extra financing; uncertainty about patent safety and litigation; uncertainty about reimbursement from governments or third-party payors; restricted analysis and improvement efforts and reliance on third events; and intense competitors. As with all drug in improvement, there are vital dangers related to the event, regulatory approval and commercialization of recent merchandise. Tonix assumes no obligation to replace or revise any forward-looking statements. Traders ought to learn the dangers set forth in our Annual Report on Type 10-Ok for the 12 months ended December 31, 2023, filed with the Securities and Alternate Fee (SEC) on April 1, 2024, and in our periodic reviews filed with the SEC issue. All of Tonix’s forward-looking statements are expressly certified by all such threat components and different cautions. The knowledge contained herein speaks solely as of the date of this data.
Investor Contact
Jessica Morris
Tonix Prescribed drugs
Investor.relations@tonixpharma.com
(862) 904-8182
Peter Vozzo
ICR Westwick
peter.vozzo@westwicke.com
(443)213-0505
Media Contact
ray jordan
Putnam Insights
ray@putnaminsights.com
(949)245-5432
Supply: Tonix Pharmaceutical Holdings, Inc.
